Menopause Hits the Skin and Hair First: A Dermatology Guide to Hormonal and Nonhormonal Care
Skin and hair changes often appear in perimenopause before hot flashes. A new dermatology review maps hormone therapy and other treatments for women.
Summary
Menopause changes the skin and hair, often before the hot flashes that usually send women to a doctor. This review, the second of two parts, explains that these changes come from falling estrogen combined with relatively higher androgen (male hormone) effects. They include a weakened skin barrier, thinner and looser skin, uneven pigmentation, hair loss or unwanted hair growth, new or worsening acne, rosacea, and vulvovaginal changes. The authors turn the biology from Part 1 into practical guidance for dermatologists. They cover menopausal hormone therapy, recent regulatory changes, and what is known about topical and systemic estrogen. They also review nonhormonal options for barrier problems, skin aging, hair and pigment disorders, acne, rosacea, and genitourinary syndrome. The authors point out which treatments have strong evidence and where evidence is thin. They also provide counseling points so women understand the benefits, limits, and uncertainties of each option.
Detailed Summary
Menopause is often thought of as a story of hot flashes and night sweats, but the skin and hair frequently change first. During perimenopause, women may notice dry, fragile skin, new wrinkles and laxity, patchy pigmentation, thinning hair, and breakouts well before other symptoms appear. This makes dermatologists an early and important part of a woman's menopause care team.
This review is Part 2 of a two-part series from dermatology authors at Emory University and Georgia Skin Specialists. Part 1 explained the biology. Part 2 turns that biology into clinical management. The authors describe how the skin and hair changes result from declining estrogen along with relative androgen excess, which can drive hair loss, unwanted hair growth, and acne.
The review covers current data on menopausal hormone therapy and what it means for the skin, including recent regulatory changes and evolving evidence on topical and systemic estrogen. It then summarizes management of skin barrier dysfunction, dermal aging, hair and pigmentary disorders, perimenopausal acne, rosacea, and genitourinary syndrome with vulvar dermatoses. Both hormonal and nonhormonal therapies are discussed.
Throughout, the authors identify therapies backed by high-quality evidence and flag areas where evidence remains limited. They also advise when to refer women to other specialists, such as gynecology or endocrinology, and offer counseling points to help women understand realistic benefits and uncertainties.
The practical message is that skin and hair symptoms are legitimate, treatable signs of the menopausal transition, not just cosmetic concerns. Clinicians can use them as an early cue to start broader menopause conversations. Because this summary draws only on the abstract, specific recommendations, dosing, and the strength of evidence for each treatment cannot be assessed here, and readers should consult the full article.
Key Findings
- Skin and hair changes in perimenopause often appear before the vasomotor symptoms that typically prompt women to seek care.
- Estrogen decline plus relative androgen excess drives barrier dysfunction, thinning, pigmentary changes, hair loss or hirsutism, and acne.
- The review covers menopausal hormone therapy, including recent regulatory changes and evolving evidence on topical and systemic estrogen.
- Management is outlined for acne, rosacea, hair and pigment disorders, dermal aging, and genitourinary syndrome with vulvar dermatoses.
- Evidence quality varies, and the authors flag where data are limited and when interdisciplinary referral is warranted.
Methodology
This is a narrative clinical review, the second in a two-part series, synthesizing current literature on menopausal skin and hair management. The abstract does not describe a formal search strategy or evidence-grading method.
Study Limitations
This summary is based on the abstract only, so specific recommendations, data, and evidence ratings are not available. As a narrative review, it may be subject to selection bias, and the abstract notes that evidence remains limited in several areas.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe:
